Acute myeloid leukemia (AML) is typically diagnosed through a combination of blood tests, a bone marrow biopsy, and genetic analysis. The process often begins with a routine blood draw that reveals abnormal cells, then moves quickly to more specialized tests that confirm the diagnosis and classify the specific subtype. Initial results can come back within a day or two, but the full genetic picture may take one to two weeks.
Blood Tests: The First Step
AML diagnosis usually starts with a complete blood count (CBC) and a peripheral blood smear, where a lab technician examines your blood under a microscope. The hallmark finding is the presence of blasts, which are immature white blood cells that normally stay in the bone marrow and never enter the bloodstream in significant numbers. In AML, these blasts often make up a large proportion of the white blood cell count and may even be the dominant cell type circulating in your blood.
Beyond the blasts themselves, the CBC typically shows a pattern of disruption across all blood cell lines. Red blood cell counts drop (anemia), platelet counts drop (thrombocytopenia), and white blood cell counts swing abnormally high or low. Under the microscope, the blasts in AML tend to be relatively large cells, and some contain distinctive needle-shaped structures called Auer rods. When a pathologist sees Auer rods, it’s a strong indicator that the leukemia is myeloid rather than another type.
Bone Marrow Biopsy
A bone marrow biopsy is essential for confirming AML. Blood tests can raise the suspicion, but the marrow is where the disease originates, and examining it directly provides the most complete picture. The procedure involves two parts done in the same session: an aspiration, which draws out a liquid sample of the marrow, and a core biopsy, which removes a small cylinder of solid marrow tissue. Each provides different information. The liquid sample is used for detailed cell analysis and genetic testing, while the solid sample shows the marrow’s overall architecture and how densely packed with abnormal cells it is.
The sample is typically taken from the back of the hipbone (the posterior iliac crest). You lie on your stomach or side, the area is numbed with local anesthetic, and the doctor makes a small incision before inserting the biopsy needle. The aspiration often causes a brief pulling sensation that local anesthetic can’t fully block, but it lasts only seconds. Pressure is applied afterward, a bandage goes on, and most people go home the same day with soreness that fades over a few days.
The 20% Blast Threshold
The traditional cutoff for diagnosing AML is 20% or more blasts in the bone marrow or blood. If a pathologist counts the cells in your sample and at least one in five is a blast, that meets the threshold. However, the most recent international classification guidelines have introduced important exceptions. When certain genetic abnormalities are present, AML can be diagnosed with as few as 10% blasts. These exceptions cover more than a dozen specific genetic subtypes, including some of the most well-known forms of the disease like acute promyelocytic leukemia and AML with specific chromosome rearrangements.
This change reflects a growing understanding that the genetic identity of the leukemia matters as much as the raw blast count. A patient with 12% blasts carrying a high-risk genetic mutation may need the same urgent treatment as someone with 40% blasts, so waiting for the count to climb would only delay care.
Flow Cytometry: Identifying the Cell Type
Once blasts are found, the next question is what kind of blasts they are. Flow cytometry answers this by tagging cells with fluorescent antibodies that bind to specific proteins on the cell surface. Each type of blood cell carries a unique combination of surface proteins, so the pattern tells doctors whether the leukemia is myeloid (AML), lymphoid (ALL), or a rarer mixed type.
For AML, the key surface markers include proteins involved in myeloid cell development. The lab runs panels testing for dozens of markers simultaneously, looking for combinations that confirm the cells are stuck at an immature stage of myeloid development. This step is critical because AML and ALL can look similar under a microscope but require completely different treatment approaches. Flow cytometry results typically come back within a day or two.
Chromosome and Genetic Testing
Genetic analysis has become one of the most important parts of an AML diagnosis because it determines both the subtype and the risk category, which directly shapes treatment decisions. Two main types of testing are performed.
Cytogenetic analysis (karyotyping) looks at the chromosomes inside leukemia cells for large-scale abnormalities: missing chromosomes, extra chromosomes, or pieces of chromosomes that have broken off and reattached in the wrong place. One of the most common findings in AML is a translocation between chromosomes 8 and 21, where segments of those two chromosomes swap places. Another well-known abnormality is an inversion of chromosome 16. Both of these are associated with a more favorable prognosis. Karyotyping requires growing cells in a lab before analysis, so results typically take 7 to 14 days.
Molecular testing looks deeper, scanning the DNA of leukemia cells for specific gene mutations. The mutations tested for in AML have direct treatment implications. FLT3 mutations, found in roughly 30% of newly diagnosed cases, involve a gene that drives cell growth. These mutations are classified as intermediate risk and are now targeted with specific drugs. Mutations in IDH1 or IDH2 genes, present in about 20% of cases, disrupt normal cell metabolism and cause immature cells to accumulate instead of maturing properly. These too have targeted therapies available. NPM1 mutations, another commonly tested gene, generally carry a more favorable outlook when found without certain co-occurring mutations.
This genetic information takes the longest to come back, sometimes up to two weeks. In many cases, doctors will begin initial treatment based on the faster results (blood counts, morphology, flow cytometry) while waiting for the full genetic profile to refine the plan.
Physical Exam and Additional Testing
The diagnostic workup also includes a physical examination. Doctors check for signs that leukemia cells have spread beyond the blood and marrow. Enlarged lymph nodes are one indicator. An enlarged liver or spleen (felt as fullness or tenderness in the abdomen) is another. AML can also infiltrate the gums, causing noticeable swelling, and less commonly the skin, where it may form firm, discolored nodules.
Imaging tests like CT scans or ultrasounds may be ordered to assess organ enlargement or look for collections of leukemia cells outside the marrow. A lumbar puncture (spinal tap) is not routine for most AML patients. It’s performed only when there are neurological symptoms suggesting the leukemia has reached the central nervous system, such as altered mental status, persistent headaches, numbness, seizures, or vision changes. Central nervous system involvement is more common in patients with very high white blood cell counts or subtypes with a strong monocytic component.
How Results Come Together
AML diagnosis isn’t a single test but a layered process. The initial blood work and bone marrow examination can confirm leukemia within 24 to 48 hours. Flow cytometry, arriving on a similar timeline, confirms it’s myeloid. Then the genetic results roll in over the following one to two weeks, progressively sharpening the picture from “you have AML” to “you have this specific subtype of AML, with this risk profile, and these targeted treatment options.” Each layer of testing adds precision, and the full diagnostic workup is what allows doctors to match treatment intensity to the biology of the individual disease.